Jefferies Boosts PT on Radius Health (RDUS) to $46 Amid Solid Physician Poll Data

August 15, 2016 8:43 AM EDT
Get Alerts RDUS Hot Sheet
Price: $43.94 -6.65%

Rating Summary:
    7 Buy, 2 Hold, 1 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 21 | Down: 36 | New: 11
Trade RDUS Now!
Join SI Premium – FREE

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies boosts its price target on Hold-rated Radius Health (Nasdaq: RDUS) from $37 to $46 today following recent physician poll results.

Analyst Eun Yang commented, Our physician poll shows convenient abalo-TD patch for osteoporosis, if successful, would increase abalo use by ~25-30% (vs. injectable abalo-SC). Given abalo-TD patch late-breaker presentation on 9/19/16 and likely positive bioequivalence data, we raise estimates and target, but the impact isn’t enough to justify a Buy. While we don't take a strong view on recent M&A speculation, some rumored buyers don't seem a right fit, in our view.

Ahead of first human PK data for RDUS’ optimized abalo-TD patch for PMO, we conducted a poll of 27 U.S. rheumatologists/endocrinologists to assess potential market expansion of abalo franchise, if successfully developed. With abalo-TD patch data in a late-breaker oral session at ASBMR on 9/19/16, we/Street assume positive data (although how good the data would be is debatable), warranting further development for potential approval. Daily SC injectable formulation of abalo (abalo-SC) is under regulatory reviews (PDUFA date 3/30/17).

Poll results show abalo-TD patch would increase physicians' utilization of abaloparatide by ~25-30% on improved convenience (vs. abalo-SC alone). Although a clear development path to approval is yet-to-be defined for abalo-TD patch, if bioequivalence data (vs. abalo-SC) are positive, we assume a likely shortened path to approval (potentially entering the market in ~2018-2019).

For an analyst ratings summary and ratings history on Radius Health click here. For more ratings news on Radius Health click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Jefferies & Co, PDUFA

Add Your Comment